Capvizr
THE DEAL, AT A GLANCE

Matisse

From the announcement
01What happenedMatisse raised $14M Series A, announced 2026-09-17From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Why it mattersMatisse is a clinical-stage sepsis drug-development financing thesis centered on using a EUR 14m Series A to advance isupartob sodium into a Phase II sepsis trial.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Matisse · Financing Record

Explore source-linked visual explanations for Matisse. Unsupported claims are withheld while source review continues.

Record 12556 · Recorded date: 2026-09-17

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime